Mode of Action Program Sample Clauses
The Mode of Action Program clause defines the procedures and standards for identifying and documenting the biological mechanism by which a product or compound achieves its intended effect. In practice, this clause may require parties to conduct specific studies, share research data, or collaborate on scientific investigations to determine how a drug or technology works at the molecular or cellular level. Its core function is to ensure that all parties have a clear, evidence-based understanding of the product's mechanism, which is essential for regulatory approval, intellectual property protection, and informed decision-making throughout the development process.
Mode of Action Program. 4.1 Provision of BMS Compounds. BMS will provide Exelixis with [ * ] BMS Compounds within [ * ] after the Effective Date, for use by Exelixis in the Mode of Action Program. BMS shall make known to Exelixis all BMS Compounds that are part of BMS Products. BMS shall not reveal the identity or structure of any BMS Compound to Exelixis, but it may provide Exelixis with information concerning the putative function of an BMS Compound or other such information as may help Exelixis perform its duties under the Mode of Action Program (which information shall be treated as BMS Confidential Information). Following approval and allocation of sufficient FTE resources by the JMT, BMS may provide additional BMS Compound sets to Exelixis from time-to-time during the Research Term for use by Exelixis in the Mode of Action Program.
(a) In the event that, subsequent to providing a BMS Compound to Exelixis, but prior to the identification by Exelixis under the Mode of Action Program of any Target modulated by such BMS Compound, BMS learns that such BMS Compound modulates a particular invertebrate or vertebrate target either: (i) from public disclosures; or (b) from internal BMS research in an area other than mode of action research using C. elegans or Drosophila, then BMS may, by providing written notice to Exelixis substantiating the basis of BMS' learning of such target, withdraw such BMS Compound from the Mode of Action Program, and Exelixis shall cease work thereon. BMS shall not use any Research Results relating to such BMS Compound, but shall have no obligation to Exelixis based on the use of any Information learned by BMS independently.
Mode of Action Program. 21 4.1 Provision of BMS Compounds................................................... 21 4.2 Stage I - Feasibility Evaluation............................................. 22 4.3 Provision and Testing of Analogues........................................... 22 4.4 Stage II - Target Identification............................................. 22 4.5 Stage III - Identification of Candidate Targets.............................. 22